Redcare Pharmacy N.V.
Redcare Pharmacy N.V. (RDC.DE) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Redcare Pharmacy N.V. (RDC.DE), covering cash flow, earnings, and balance sheets.
Redcare Pharmacy N.V. (RDC.DE) Income Statement & Financial Overview
Review Redcare Pharmacy N.V. RDC.DE income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $717.29M | $675.14M | $574.55M | $560.67M |
| Cost of Revenue | $550.00M | $524.68M | $441.23M | $446.62M |
| Gross Profit | $167.29M | $150.45M | $133.31M | $114.06M |
| Gross Profit Ratio | $0.23 | $0.22 | $0.23 | $0.20 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $176.70M | $170.44M | $140.17M | $134.33M |
| Operating Expenses | $176.38M | $174.06M | $139.97M | $117.25M |
| Total Costs & Expenses | $726.38M | $698.75M | $581.20M | $563.87M |
| Interest Income | $1.14M | $371000.00 | $3.03M | $1.66M |
| Interest Expense | $4.86M | $4.03M | $4.05M | $3.81M |
| Depreciation & Amortization | $16.83M | $5.53M | $17.10M | $17.08M |
| EBITDA | $9.20M | -$14.55M | $13.47M | $15.71M |
| EBITDA Ratio | $0.01 | -$0.02 | $0.02 | $0.03 |
| Operating Income | -$9.09M | -$23.61M | -$6.66M | -$3.19M |
| Operating Income Ratio | -$0.01 | -$0.03 | -$0.01 | -$0.006 |
| Other Income/Expenses (Net) | -$3.39M | -$2.88M | -$899000.00 | -$2.15M |
| Income Before Tax | -$12.48M | -$26.50M | -$7.55M | -$5.18M |
| Income Before Tax Ratio | -$0.02 | -$0.04 | -$0.01 | -$0.009 |
| Income Tax Expense | -$862000.00 | -$218000.00 | -$448000.00 | -$396000.00 |
| Net Income | -$10.82M | -$26.48M | -$6.91M | -$4.27M |
| Net Income Ratio | -$0.02 | -$0.04 | -$0.01 | -$0.008 |
| EPS | -$0.54 | -$1.32 | -$0.35 | -$0.21 |
| Diluted EPS | -$0.54 | -$1.32 | -$0.35 | -$0.21 |
| Weighted Avg Shares Outstanding | $20.11M | $20.11M | $20.02M | $19.89M |
| Weighted Avg Shares Outstanding (Diluted) | $20.11M | $20.11M | $20.02M | $19.89M |
The company's financials show resilient growth, with revenue advancing from $560.67M in Q2 2024 to $717.29M in Q1 2025. Gross profit remained healthy with margins at 23% in Q1 2025 compared to 20% in Q2 2024. Operating income hit -$9.09M last quarter, sustaining a consistent -1% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $9.20M. Net income rose to -$10.82M, while earnings per share reached -$0.54. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan